These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 9559796)

  • 1. Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
    Hoellman DB; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Apr; 42(4):857-61. PubMed ID: 9559796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity.
    Muñoz Bellido JL; Muñoz Criado S; García García I; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; García-Rodríguez JA
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2612-5. PubMed ID: 9420028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
    Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods.
    Visalli MA; Jacobs MR; Moore TD; Renzi FA; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Apr; 41(4):767-70. PubMed ID: 9087486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
    Thomson KS; Weber DA; Sanders CC; Sanders WE
    Antimicrob Agents Chemother; 1990 Apr; 34(4):622-7. PubMed ID: 2344169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ; Prior RB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2905-7. PubMed ID: 7695281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods.
    Pankuch GA; Jacobs MR; Rittenhouse SF; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2317-22. PubMed ID: 7840563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci.
    Pankuch GA; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1499-504. PubMed ID: 7492093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus.
    Rand KH; Houck HJ
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2871-5. PubMed ID: 15273094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.
    Cherubin CE; Eng RH; Smith SM; Tan EN
    J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam.
    Okhuysen PC; Singh KV; Murray BE
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):219-24. PubMed ID: 8112031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides.
    Joly-Guillou ML; Decré D; Herrman JL; Bourdelier E; Bergogne-Bérézin E
    J Antimicrob Chemother; 1995 Oct; 36(4):619-29. PubMed ID: 8591936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.